Should I buy Hims & Hers Health (HIMS) stock or is it too late?

Hims & Hers Health · Health Care · price $30

See the full Hims & Hers Health (HIMS) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: B of A Securities — 74% of its targets hit on this sector (109 calls tested). It aims for $32 (+7.7 %), call made on August 12, 2026, maturing on August 12, 2027 (63 d ago).

The 5 reliable analysts $32+7.7 %

The 5 other firms $35+18 %

How to read it: the 5 reliable firms are not filtered by optimism — 4 aim above the price, 1 below, hence their $32 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Hims & Hers Health

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
B of A Securities	92 %	+75.4 %	13	$32 +8%
Canaccord Genuity	67 %	+55.9 %	6	$40 +35%
Citigroup	70 %	+49.4 %	10	$33 +11%
Needham	40 %	+9.8 %	5	$42 +41%

In short — Should you invest in Hims & Hers Health? Is it too late, still worth it? Analysts are split (36% buy, median target $33, i.e. +9%), and the most reliable on HIMS targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $33, i.e. +9% from the current price ($30).
The most reliable firm on HIMS, TD Cowen (100% hit rate, 4 scored calls), targets $30 (call made on August 11, 2026, maturing on August 11, 2027) (+1%) in its most recent call, and $20 (call made on February 9, 2026, maturing on February 9, 2027) (-33%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 11 ratings, 7 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on HIMS

Median target $33 (+9%) · 11 ratings · Hold consensus

Strong Buy00%

Buy436%

Hold764%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Hims & Hers Health now?

We won't decide for you. The facts: 36% of analysts rate it a buy, median target $33 (+9%), and TD Cowen (most reliable on HIMS, 100%) targets $30. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Hims & Hers Health?

Not according to analysts: the median target ($33) is still +9% above the current price ($30) (most reliable on HIMS: TD Cowen, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Hims & Hers Health still worth investing in?

It depends on the gap between the price ($30) and its estimated value: analysts target $33 on median (+9%), with 36% buys (most reliable on HIMS: TD Cowen, 100%). Cross-check with their real reliability on HIMS and the cautions above. Information, not advice.

What's the main risk in buying HIMS?

The consensus is not unanimous: of 11 ratings, 7 are neutral.

→ Go deeper: the full Hims & Hers Health profile (consensus, analyst reliability, price target, performance).